MILFORD, Mass., July 27, 2026
Waters Corporation has introduced the Xevo™ TQ Absolute XR IVD Mass Spectrometer, expanding its MassTrak™ IVD LC-MS/MS Systems portfolio with what the company describes as the industry’s most sensitive and robust clinical in vitro diagnostic (IVD) mass spectrometry system. Designed for routine clinical laboratory testing, the new platform combines industry-leading tandem quadrupole mass spectrometry sensitivity with significantly improved robustness, enabling laboratories to achieve lower detection limits, analyze smaller biological sample volumes, and improve operational efficiency. The system delivers up to five times greater sensitivity than comparable instruments in its class while offering up to six times greater robustness through the new StepWave™ XR Ion Guide technology. These advancements are expected to support growing clinical demand across women’s health diagnostics, cancer assessment, clinical toxicology, and other high-complexity laboratory applications where accurate trace-level analysis is essential. By strengthening its advanced diagnostics portfolio, Waters continues to expand the role of LC-MS/MS technology in precision diagnostics and modern clinical laboratory medicine.
New Xevo TQ Absolute XR Delivers Exceptional Sensitivity
The Xevo TQ Absolute XR IVD Mass Spectrometer has been engineered to provide laboratories with superior analytical performance when measuring low-abundance biomarkers in complex biological samples. According to Waters, the platform delivers up to five-fold higher sensitivity than comparable IVD-compliant tandem quadrupole mass spectrometers, allowing laboratories to detect extremely low analyte concentrations while requiring smaller sample volumes. This enhanced analytical capability is particularly valuable for low-level estradiol testing in women’s health, hormone-related cancer assessment, and hair toxicology testing for drugs of abuse and long-term exposure monitoring. The increased sensitivity enables laboratories to generate more reliable quantitative results near clinical decision thresholds, supporting improved diagnostic confidence while expanding testing capabilities for challenging clinical assays. As demand grows for highly sensitive molecular and biochemical testing, Waters’ latest innovation positions clinical laboratories to perform increasingly sophisticated diagnostic analyses with greater precision and efficiency.
StepWave XR Technology Improves Laboratory Productivity
A major innovation within the new system is the integration of the StepWave™ XR Ion Guide, which significantly enhances instrument robustness during routine analysis of complex biological matrices containing phospholipids, salts, proteins, and other interfering compounds. Waters reports that the new technology delivers up to six times longer ion ratio consistency compared with the previous Xevo TQ Absolute IVD System, helping laboratories reduce downtime, maintain consistent analytical performance, and improve workflow productivity. The complete MassTrak™ LC-MS/MS IVD System integrates the ACQUITY™ UPLC I-Class PLUS System with the new mass spectrometer, providing fast chromatographic separation, simplified sample analysis, and improved instrument uptime. These improvements are especially valuable for high-volume clinical laboratories that require continuous operation while maintaining strict regulatory compliance and analytical accuracy across large numbers of patient samples.
Advertisement
Advancing Clinical Diagnostics with Next-Generation Mass Spectrometry
The launch of the Xevo TQ Absolute XR IVD System reflects the growing importance of mass spectrometry-based diagnostics in modern healthcare, where laboratories increasingly rely on highly sensitive technologies to support precision medicine, endocrinology, oncology, and clinical toxicology. By combining advanced LC-MS/MS instrumentation, improved robustness, and greater analytical sensitivity, Waters aims to help laboratories expand their testing capabilities while improving confidence in complex clinical measurements. As healthcare providers continue adopting advanced molecular diagnostic technologies to support earlier disease detection and personalized patient care, innovations such as the Xevo TQ Absolute XR are expected to play an increasingly important role in enhancing laboratory performance and delivering more accurate clinical results. The system is now available for commercial ordering and further strengthens Waters’ leadership in clinical diagnostics, life sciences, and analytical instrumentation.
Source: Waters Corporation press release
